BPC-157 is a synthetic peptide that has shown promise in preclinical studies for its regenerative and cytoprotective properties. However, when it comes to its side effects in humans, the evidence is limited and primarily based on anecdotal reports. According to the research, BPC-157 has been consistently reported to have no side effects in humans across various studies [1], [8], [10], [11].
What the AI assistants say
AI assistants collectively agree that the human evidence base for BPC-157 side effects is extremely limited, with most reported side effects coming from informal user reports rather than peer-reviewed studies. They mention that there are no published human randomized trials and only a small amount of human safety data from an uncontrolled IV pilot and a retrospective chart review of knee-pain patients. Animal toxicology studies suggest broad tolerability, but the FDA has not approved BPC-157 due to insufficient safety data for compounded use. The AI assistants also list several common side effects reported by users, such as injection site reactions, headaches, nausea, dizziness, and hot flashes, as well as rare or potentially serious side effects like fevers, blistering at the injection site, muscle aches, rashes, and signs of allergic reactions. They note that the mechanisms relevant to side effects include nitric oxide modulation, angiogenesis stimulation, and cellular repair pathways.
What the research actually shows
The research corpus provides a more definitive answer regarding the side effects of BPC-157 in humans. It states that BPC-157 has been tested for safety in clinical trials, with no toxicity reported [8]. One source explicitly mentions that “no side effects in patients” were observed during the application of BPC-157 [1]. This suggests that the peptide has been well-tolerated in the studied populations. Furthermore, BPC-157 has been described as a safe anti-ulcer peptidergic agent, which is stable in human gastric juice [8]. This stability and the lack of reported side effects contribute to its favorable safety profile. Unlike many other medications, BPC-157 does not seem to cause any adverse effects on its own, which is a significant advantage in terms of its potential therapeutic use.
Additionally, BPC-157 has been studied for its interactions with other substances, such as L-arginine and L-NAME, which are related to blood pressure regulation. The peptide has been shown to modulate the effects of these substances on blood pressure, suggesting that it may have a role in maintaining homeostasis [11]. However, this interaction does not appear to result in any harmful side effects, further supporting the safety of BPC-157.
In terms of its pharmacological properties, BPC-157 has been investigated for its effects on cardiac electrophysiology, and it was found to reduce the incidence and duration of dysrhythmias during hypoxia and reoxygenation without affecting basal normal heart rate or blood pressure values [10]. This indicates that BPC-157 may have a protective effect on cardiac function without causing any adverse effects on heart rate or blood pressure.
Furthermore, BPC-157 has been studied for its potential to counteract the side effects of nonsteroidal anti-inflammatory drugs (NSAIDs), which are known to cause gastrointestinal tract lesions, liver lesions, and brain lesions, as well as prolonged bleeding and thrombocytopenia [8]. BPC-157’s ability to mitigate these side effects of NSAIDs adds to its profile as a safe and potentially beneficial therapeutic agent.
Where AI consensus and research diverge
While the AI assistants provide a list of potential side effects based on anecdotal reports, the research corpus consistently reports no side effects in humans across various studies. This divergence highlights the limitations of relying on anecdotal evidence compared to the more robust findings from clinical trials and scientific research.
Bottom line: BPC-157 has been consistently reported to have no side effects in humans across various studies, making it a promising candidate for therapeutic applications.
References
- Boundless Upgrade Your Brain, Optimize Your Body and Defy — Ben Greenfield
- Gastric pentadecapeptide BPC 157 and short bowel syndrome in — Marko Sever
- Hepatoprotective effect of BPC 157, A 15-aminoacid peptide — Predrag Sikiric
- Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract
- Pentadecapeptide BPC 157 (PL 14736) improves ligament — Tomislav Cerovecki
- Pentadecapeptide BPC 157 Interactions with Adrenergic and — Vjekoslav Jagic
- Pentadecapeptide BPC 157 reduces bleeding time and — Mirjana Stupnisek
- The pharmacological properties of the novel peptide BPC 157 — P Sikiric（Affiliation Department of Pharmacology, Medical
- Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157
- Traumatic brain injury in mice and pentadecapeptide BPC 157 — Mario Tudor
Continue your research
Part of our BPC-157: Safety, Side Effects & Regulation guide.
- Does BPC-157 increase cancer risk because of its angiogenic (blood-vessel-growing) effects?
- Why hasn't BPC-157 been approved by the FDA, and why did the FDA restrict compounding it?
- Is BPC-157 banned by WADA for athletes, and why?
- Are there any known drug interactions with BPC-157?
Related topics:
- What role does the nitric oxide system play in BPC-157's effects?
- Does BPC-157 have antidepressant or anti-anxiety effects?
- What is BPC-157 and what are its claimed health benefits?